Natalizumab (ITGA4/CD49d) Antibody, Monoclonal | 10-090

Natalizumab (ITGA4/CD49d) Antibody, Monoclonal | 10-090 | Gentaur UK, US & Europe Distribution

Host: N/A

Reactivity: N/A

Homology: N/A

Immunogen: Humanized / ITGA4/CD49d [Homo sapiens]

Research Area: Drug Analogues

Tested Application: N/A

Application: N/A

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: >95%

Clonality: Monoclonal

Clone: N/A

Isotype: IgG4-kappa

Conjugate: Unconjugated

Physical State: N/A

Buffer: PBS buffer pH7.5

Concentration: N/A

Storage Condition: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚C for 1-2 weeks. Store at -20 ˚C for 12 months. Store at -80 ˚C for long term storage.

Alternate Name: AN 100226, BG00002, ITGA4/CD49d, ITGA4/CD49d

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Natalizumab is a recombinant, humanized monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1) .Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease.Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses.